Importantly, FP‐1039 (GSK3052230), a FGF2 trap molecule, was tested in a clinical phase IB trial for patients with malignant pleural mesothelioma (ClinicalTrials.gov NCT01868022),[15] highlighting that the road leading to development of FGF2 blocking molecules is still rugged but promising. The gene discussed is FGF2; the disease is malignant pleural mesothelioma.